Market Overview

Perrigo Announces FDA Final Approval for Generic Version of Vanos Cream 0.1%

Perrigo (NYSE: PRGO; TASE) today announced that it has received final approval for its abbreviated new drug application ("ANDA") for fluocinonide cream 0.1%, the generic equivalent to Vanos® Cream 0.1%. Perrigo was awarded 180-days of generic drug exclusivity as it was the first company to submit an ANDA containing a paragraph IV certification. Perrigo had previously resolved litigation with the brand and has commenced shipment of the product.

See full press release

Posted-In: News Guidance Offerings Contracts FDA Management Global

 

Related Articles

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters